Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to -$8.2 million.

  • Benitec Biopharma's Cash from Operations fell 14977.22% to -$8.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$23.6 million, marking a year-over-year decrease of 2163.07%. This contributed to the annual value of -$23.6 million for FY2025, which is 2163.07% down from last year.
  • Benitec Biopharma's Cash from Operations amounted to -$8.2 million in Q2 2025, which was down 14977.22% from -$3.1 million recorded in Q1 2025.
  • Benitec Biopharma's 5-year Cash from Operations high stood at -$2.0 million for Q1 2021, and its period low was -$8.2 million during Q2 2025.
  • In the last 5 years, Benitec Biopharma's Cash from Operations had a median value of -$4.4 million in 2021 and averaged -$4.7 million.
  • As far as peak fluctuations go, Benitec Biopharma's Cash from Operations crashed by 16007.8% in 2021, and later soared by 4996.76% in 2025.
  • Benitec Biopharma's Cash from Operations (Quarter) stood at -$3.3 million in 2021, then plummeted by 76.25% to -$5.9 million in 2022, then grew by 8.76% to -$5.3 million in 2023, then tumbled by 43.93% to -$7.7 million in 2024, then dropped by 6.97% to -$8.2 million in 2025.
  • Its Cash from Operations stands at -$8.2 million for Q2 2025, versus -$3.1 million for Q1 2025 and -$7.7 million for Q4 2024.